問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-Department of Medical Imaging

Division of Radiology

Division of Nuclear Medicine

Division of Neurology

Division of Hematology & Oncology

更新時間:2023-09-19

陳雅芳CHEN, YA-FANG
  • Principal Investigator
  • Clinical Trial Experience (year) 8 years

篩選

List

60Cases

2022-12-01 - 2024-07-08

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-08-14 - 2027-07-24

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-05-18 - 2026-08-21

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-02-17 - 2028-10-10

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-06-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2017-01-15 - 2020-02-28

Phase II

An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
  • Condition/Disease

    Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
5Sites

Terminated5Sites